Stifel cuts Arcellx stock rating on Gilead acquisition deal
#Arcellx#Gilead Sciences#Stock Rating#Acquisition Deal#CAR T-cell therapy#Contingent Value Right#Biotech Mergers#Analyst Downgrade
📌 Key Takeaways
Stifel downgraded Arcellx from Buy to Hold with a reduced price target of $115
The downgrade follows Gilead Sciences' proposed $7.8 billion acquisition of Arcellx
The acquisition includes a $5 per share contingent value right based on sales performance
Arcellx stock has surged 62% in the past week following the acquisition announcement
Multiple analyst firms have adjusted their ratings for Arcellx following the acquisition news
📖 Full Retelling
Stifel downgraded Arcellx Inc. (NASDAQ:ACLX) to Hold from Buy and lowered its price target to $115 from $127 on February 24, 2026, following the proposed $7.8 billion acquisition by Gilead Sciences. The downgrade reflects the proposed acquisition by collaborative partner Gilead for $7.8 billion in implied equity value and a $5 per share contingent value right payment triggered by cumulative global net sales exceeding $6 billion through fiscal year 2029. The Boards of both companies have approved the proposed acquisition price. Stifel continues to believe the likely year-end 2026 approval of anito-cel in fourth-line and later patients will result in one of the most successful oncology launches. Longer-term label expansion into second-line and later patients per Phase 3 iMMagine-3 data serves as the primary lever underlying the firm's $7 billion peak global sales estimate. The firm reduced its target price to $115 from $127 to reflect the proposed acquisition price. The stock currently trades at $113.75, up 62% in the past week following the acquisition announcement, bringing its year-to-date gain to 74%. Stifel's estimates for Arcellx remain unchanged. The acquisition includes a contingent value right structure tied to future sales performance through 2029. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value. Following the acquisition announcement, several analyst firms adjusted their ratings for Arcellx, with Evercore ISI downgrading to In Line from Outperform, Truist Securities downgrading to Hold from Buy, and Rothschild Redburn downgrading to Neutral from Buy citing competition concerns.
🏷️ Themes
Biotech Acquisitions, Stock Market Analysis, Pharmaceutical Industry
Gilead Sciences, Inc. () is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir....
This acquisition is significant because it gives Gilead Sciences full control over a promising CAR T-cell therapy for multiple myeloma, solidifying its position in oncology. The deal's structure includes a contingent value right tied to future sales, making its ultimate value dependent on the therapy's commercial success. Analyst downgrades reflect that the acquisition price largely captures Arcellx's near-term value, limiting further upside for independent shareholders.
Context & Background
Arcellx is a biotech company developing anito-cel, a CAR T-cell therapy for multiple myeloma.
Gilead Sciences is acquiring Arcellx for $115 per share, with a total implied equity value of $7.8 billion.
The deal includes a $5 per share contingent value right payment triggered by sales targets.
Stifel downgraded Arcellx to Hold, aligning its price target with the acquisition offer.
The stock surged 62% in the week following the acquisition announcement.
What Happens Next
The acquisition is subject to regulatory approval and shareholder votes, with completion expected later in 2026. The focus will shift to the expected year-end 2026 regulatory decision for anito-cel in fourth-line multiple myeloma patients. Gilead will then work on expanding the therapy's label to earlier lines of treatment based on Phase 3 trial data.
Frequently Asked Questions
Why did Stifel downgrade Arcellx stock?
Stifel downgraded Arcellx to Hold because the acquisition price from Gilead Sciences largely reflects the company's current value, leaving limited potential for significant stock price appreciation for independent shareholders.
What is the contingent value right in the deal?
It is an additional $5 per share payment to Arcellx shareholders, triggered if cumulative global net sales of the therapy exceed $6 billion through fiscal year 2029.
What is anito-cel?
Anito-cel is a CAR T-cell therapy developed by Arcellx for treating multiple myeloma, which is a type of blood cancer.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Asia stocks rise as China reopens on a strong note; Hong Kong hit by tech losses Wall Street slides on Trump tariff turmoil, AI disruption research report Dystopian AI report sinks payment and software stocks Gold prices rise as Trump tariff turmoil boosts safe haven demand (South Africa Philippines Nigeria) Stifel cuts Arcellx stock rating on Gilead acquisition deal By Investing.com Analyst Ratings Published 02/24/2026, 01:25 AM Stifel cuts Arcellx stock rating on Gilead acquisition deal 0 GILD -1.04% ACLX 77.43% Investing.com - Stifel downgraded Arcellx Inc. (NASDAQ:ACLX) to Hold from Buy and lowered its price target to $115 from $127 following the proposed acquisition by Gilead Sciences . The downgrade reflects the proposed acquisition by collaborative partner Gilead for $7.8 billion in implied equity value and a $5 per share contingent value right payment triggered by cumulative global net sales exceeding $6 billion through fiscal year 2029. The Boards of both companies have approved the proposed acquisition price. Stifel continues to believe the likely year-end 2026 approval of anito-cel in fourth-line and later patients will result in one of the most successful oncology launches. Longer-term label expansion into second-line and later patients per Phase 3 iMMagine-3 data serves as the primary lever underlying the firm’s $7 billion peak global sales estimate. The firm reduced its target price to $115 from $127 to reflect the proposed acquisition price. The stock currently trades at $113.75, up 62% in the past week following the acquisition announcement, bringing its year-to-date gain to 74%. Stifel’s estimates for Arcellx remain unchanged. The acquisition includes a contingent value right structure tied to future sales performance through 2029. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value, which investors can explore further on the platform’s Most Overvalued ...
